June 23, 2017
bluebird bio
bluebird bio Announces Early Data from Phase 3 Northstar-2 (HGB-207) Study of LentiGlobinTM Drug Product at European Hematology Association (EHA) Annual Meeting
June 23, 2017
bluebird bio
bluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease (SCD) at European Hematology Association (EHA) Annual Meeting
June 23, 2017
GBT
Global Blood Therapeutics Announces New Data Supporting Ongoing Clinical Development of GBT440 in Adolescents with Sickle Cell Disease
June 16, 2017
Neon Therapeutics
Dr. Yasir Al-Wakeel Joins Neon Therapeutics as Chief Financial Officer
June 13, 2017
Editas Medicine
Editas Medicine to Participate in Investor Conferences in June